Irbesartan in heart failure with preserved systolic function (I-PRESERVE)
Latest Information Update: 26 Dec 2023
At a glance
- Drugs Irbesartan (Primary)
- Indications Heart failure
- Focus Registrational; Therapeutic Use
- Acronyms I-PRESERVE
- Sponsors Bristol-Myers Squibb
- 20 Dec 2023 Results assessing whether higher BUN/Cr is associated with worse outcomes in patients with chronic HF by deriving data from PARADIGM-HF, ATMOSPHERE & DAPA-HF and PARAGON-HF & I-PRESERVE, published in the European Journal of Heart Failure
- 13 Nov 2023 Results of cost-effectiveness analysis of sacubitril-valsartan in patients with HFmrEF/HFpEF , based on clinical event rates were based on 5-year data from the I-PRESERVE and event rates observed in the pooled analysis of the PARAGON-HF and PARAGLIDE-HF , presented at the American Heart Association Scientific Sessions 2023
- 01 Jul 2023 Results of pooled analysis (n=8924 from studies NCT00095238 and NCT01920711) Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation published in the Circulation: Heart Failure